Obesity Medicine

Latest News

Incretin-Based Obesity Medications Show Minimal Lean Muscle Mass Loss in 6-Month Prospective Study / image courtesy of Weight Wellness Medicine
Incretin-Based Obesity Medications Show Minimal Lean Muscle Mass Loss in 6-Month Prospective Study

April 10th 2025

Loss of lean muscle mass along with fat mass is a concerning side effect of the incretin-based antiobesity medications, making the new study results encouraging.

Switching to Tirzepatide Outweighs Escalating Dulaglutide Dose in T2D: SURPASS-SWITCH Trial
Switching to Tirzepatide Outweighs Escalating Dulaglutide Dose in T2D: SURPASS-SWITCH Trial

April 4th 2025

Responsive Parenting Intervention Curbs Childhood Obesity Risk: Daily Dose / image credit: ©New Africa/AdobeStock
Responsive Parenting Intervention Curbs Childhood Obesity Risk: Daily Dose

April 3rd 2025

ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study
ACC 2025: Cardiovascular Benefits of Semaglutide 2.4 mg Highlighted in Real-World Study

April 1st 2025

CagriSema Achieves Significant Weight Loss in Phase 3 Trial: Daily Dose / image credit: ©New Africa/AdobeStock
CagriSema Achieves Significant Weight Loss in Phase 3 Trial: Daily Dose

March 31st 2025

More News

© 2025 MJH Life Sciences

All rights reserved.